The Patent Finder
SA

Sanofi-Aventis

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

13 patents currently held

72 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
20 more records may belong here and await a decision; they are not counted.

The next term ends in Nov 2027. from the record

Of the 72 now held by other companies, 63 name Sanofi as their current owner, and 9 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Nov 2027
Next term end
8
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
Cited by 33 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Sanofi
Ends May 2029 · High confidence
Also notable
Cited by 24 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
now held by Sanofi
Ends May 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 9, 2027
    The maintenance fee for Compositions Comprising Anti-CD38 Antibodies and Lenalidomide (US 10,342,869) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
  • 1 fee due May 3, 2027
    The maintenance fee for Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use (US 9,175,087) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 2 fees due Jul 5 to 26, 2027 · next Jul 5
  • 1 fee due Sep 26, 2027
    The maintenance fee for Methods of Treating Multiple Myeloma (US 11,939,390) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 17, 2026
  • 3 terms have ended since Aug 17, 2026

What they patent

The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US D693,457Inhaler
In force
 · High confidence
In forceHigh confidence
US 8,980,262Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use
held by Sanofi
In force
 · High confidence
In forceHigh confidence
US 9,175,087Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use
held by Sanofi
In force
 · High confidence
In forceHigh confidence
US 9,228,019Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use
held by Sanofi
In force
 · High confidence
In forceHigh confidence
US 9,243,067Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use
held by Sanofi
In force
 · High confidence
In forceHigh confidence
US 9,815,902Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses
held by Sanofi
In force
 · High confidence
In forceHigh confidence
US 8,647,309Medication Delivery Device
In force
 · High confidence
In forceHigh confidence
US 8,153,765Novel ANTI-CD38 Antibodies for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 10,342,869Compositions Comprising Anti-CD38 Antibodies and Lenalidomide
In force
 · High confidence
In forceHigh confidence
US 12,533,411Compositions Comprising ANTI-CD38 Antibodies and Carfilzomib
In force
 · High confidence
In forceHigh confidence
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 72 patents in force now held by others · 630 patents ended · 15 applications pending · 289 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited